Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population

Taro Kishi, Tsuyoshi Kitajima, Masashi Ikeda, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Tomo Okochi, Norio Ozaki, Nakao Iwata

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively influences clinical status. Treatment with antidepressants also reportedly affects circadian rhythms. In a recent in vitro study, the nuclear receptor Rev-erbα was reported to be related to circadian rhythms, and was shown to be involved in the biological action of lithium therapy. Therefore, we examined the association between the orphan nuclear receptor Rev-erbα gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder. Methods: The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in NR1D1 for the following association analysis. Results: We did not detect a significant association between NR1D1 and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. Conclusion: Our results suggest that NR1D1 does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.

Original languageEnglish
Pages (from-to)234-238
Number of pages5
JournalNeuropsychobiology
Volume59
Issue number4
DOIs
Publication statusPublished - 01-08-2009

Fingerprint

Orphan Nuclear Receptors
Fluvoxamine
Major Depressive Disorder
Population
Genes
Circadian Rhythm
rev Genes
Therapeutics
Cytoplasmic and Nuclear Receptors
Lithium
Haplotypes
Antidepressive Agents
Single Nucleotide Polymorphism
Sleep
Alleles
Genotype
Interviews
Depression

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Kishi, Taro ; Kitajima, Tsuyoshi ; Ikeda, Masashi ; Yamanouchi, Yoshio ; Kinoshita, Yoko ; Kawashima, Kunihiro ; Okochi, Tomo ; Ozaki, Norio ; Iwata, Nakao. / Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. In: Neuropsychobiology. 2009 ; Vol. 59, No. 4. pp. 234-238.
@article{1702410432ef4b2fb9ab21fcbe635f27,
title = "Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population",
abstract = "Background: Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively influences clinical status. Treatment with antidepressants also reportedly affects circadian rhythms. In a recent in vitro study, the nuclear receptor Rev-erbα was reported to be related to circadian rhythms, and was shown to be involved in the biological action of lithium therapy. Therefore, we examined the association between the orphan nuclear receptor Rev-erbα gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder. Methods: The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50{\%} in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in NR1D1 for the following association analysis. Results: We did not detect a significant association between NR1D1 and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. Conclusion: Our results suggest that NR1D1 does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.",
author = "Taro Kishi and Tsuyoshi Kitajima and Masashi Ikeda and Yoshio Yamanouchi and Yoko Kinoshita and Kunihiro Kawashima and Tomo Okochi and Norio Ozaki and Nakao Iwata",
year = "2009",
month = "8",
day = "1",
doi = "10.1159/000226612",
language = "English",
volume = "59",
pages = "234--238",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "4",

}

Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population. / Kishi, Taro; Kitajima, Tsuyoshi; Ikeda, Masashi; Yamanouchi, Yoshio; Kinoshita, Yoko; Kawashima, Kunihiro; Okochi, Tomo; Ozaki, Norio; Iwata, Nakao.

In: Neuropsychobiology, Vol. 59, No. 4, 01.08.2009, p. 234-238.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population

AU - Kishi, Taro

AU - Kitajima, Tsuyoshi

AU - Ikeda, Masashi

AU - Yamanouchi, Yoshio

AU - Kinoshita, Yoko

AU - Kawashima, Kunihiro

AU - Okochi, Tomo

AU - Ozaki, Norio

AU - Iwata, Nakao

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively influences clinical status. Treatment with antidepressants also reportedly affects circadian rhythms. In a recent in vitro study, the nuclear receptor Rev-erbα was reported to be related to circadian rhythms, and was shown to be involved in the biological action of lithium therapy. Therefore, we examined the association between the orphan nuclear receptor Rev-erbα gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder. Methods: The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in NR1D1 for the following association analysis. Results: We did not detect a significant association between NR1D1 and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. Conclusion: Our results suggest that NR1D1 does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.

AB - Background: Sleep-wake disturbance, frequently observed in major depressive disorder (MDD), negatively influences clinical status. Treatment with antidepressants also reportedly affects circadian rhythms. In a recent in vitro study, the nuclear receptor Rev-erbα was reported to be related to circadian rhythms, and was shown to be involved in the biological action of lithium therapy. Therefore, we examined the association between the orphan nuclear receptor Rev-erbα gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder. Methods: The scores of the MDD patients in this study on the 17 items of the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) were 12 or higher. We defined a clinical response as a decrease of more than 50% in baseline SIGH-D within 8 weeks and clinical remission as a SIGH-D score of less than 7 at 8 weeks. We selected 3 'tagging SNPs' in NR1D1 for the following association analysis. Results: We did not detect a significant association between NR1D1 and the fluvoxamine therapeutic response in MDD in allele/genotype-wise analysis or haplotype-wise analysis. Conclusion: Our results suggest that NR1D1 does not play a major role in the therapeutic response to fluvoxamine in Japanese MDD patients. However, because our sample was small, a replication study using another population and a larger sample will be required for conclusive results.

UR - http://www.scopus.com/inward/record.url?scp=67649442738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649442738&partnerID=8YFLogxK

U2 - 10.1159/000226612

DO - 10.1159/000226612

M3 - Article

C2 - 19571598

AN - SCOPUS:67649442738

VL - 59

SP - 234

EP - 238

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 4

ER -